Pathogenic profiles and antimicrobial resistance in neutropenic acute leukemia patients: diagnostic potential of sTNF-R1 and IL-8 - Takeaways - MDSpire

Pathogenic profiles and antimicrobial resistance in neutropenic acute leukemia patients: diagnostic potential of sTNF-R1 and IL-8

  • By

  • Yuan Zhang

  • Rong Wang

  • Guoqing Lv

  • Lihua Wang

  • July 1, 2026

  • 0 min

Share

  • 1

    The study analyzed infections in 142 acute leukemia patients during neutropenia, identifying 63 with hospital-acquired infections.

  • 2

    Bloodstream and respiratory tract infections were the most common, with 63.38% of isolated strains being Gram-negative bacteria.

  • 3

    High antimicrobial resistance rates were noted, particularly to ampicillin in Gram-negative bacteria and penicillin in Gram-positive bacteria.

  • 4

    Elevated levels of sTNF-R1 and IL-8 were significantly associated with infections, showing good diagnostic performance for early detection.

  • 5

    The combined ROC curve analysis indicated an AUC of 0.932 for sTNF-R1 and IL-8, suggesting their utility in screening infections in this population.

Original Source(s)

Pathogenic profiles and antimicrobial resistance in neutropenic acute leukemia patients: diagnostic potential of sTNF-R1 and IL-8

  • by Yuan Zhang, Rong Wang, Guoqing Lv, Lihua Wang

  • July 1, 2026

Related Content

Risk factors associated with aggressive tumor phenotypes in papillary thyroid microcarcinoma: a systematic review and meta-analysis

ASCO26: Toni Choueiri, MD, KEYNOTE-654

Data highlights limitations of ctDNA assay used to predict outcomes in participants with renal cell carcinoma treated with adjuvant pembrolizumab in the KEYNOTE-564 trial. Dana-Farber Cancer Institute's Dr. Toni Choueiri explains that ctDNA+ was associated with worse disease-free outcomes, but sensitivity was low.

  • July 1, 2026

  • 1 min
ASCO26: Michael Hassett, MD, MPH, eSyM

Dr. Michael Hassett of Dana-Farber Cancer Institute shared new findings showing deployment of eSyM, an ePRO-based, EHR-integrated symptom management program, was associated with statistically significant and potentially meaningful improvements in overall survival. Strategies to improve adoption of ePRO-based symptom management may be warranted.

  • July 1, 2026

  • 1 min